

Please join 'EMA Transparency Initiative'

- A mass public request for EMA to release key information on the residual DNA present in modified mRNA vaccines.
- Submit this request on **Saturday 15th February 2025**.
- Any European resident can participate.
- Please ensure that you follow up when EMA replies as they will send out the documents via a link.

What to do

1. Go to <https://www.ema.europa.eu/en/about-us/contacts-european-medicines-agency/send-question-european-medicines-agency>
2. Fill out the online form according to the following:

The image shows a screenshot of the EMA 'Your question' form. Red arrows point from specific fields to a green box on the right containing instructions. The instructions are: 'Enter your name' (pointing to the name fields), 'Enter "Not applicable"' (pointing to the Organisation field), 'Choose "Patient " or " Consumer"' (pointing to the 'Who are you?' dropdown), 'Enter your country' (pointing to the Location dropdown), 'Click "unpublished document"' (pointing to the 'I want an unpublished document' radio button), 'Enter "Comirnaty/Spikevax"' (pointing to the 'What is the subject of your enquiry?' field), 'Copy & paste text on next page' (pointing to the 'Your question(s)' text area), 'Enter your email address' (pointing to the 'Your email address' field), 'Confirm your email address' (pointing to the 'Please retype your email address' field), and 'Agree and SUBMIT' (pointing to the 'Send question' button).

Your question

Your name
Title First name Surname

Organisation/Employer
Organisation
If you are not representing a particular organisation please write 'Not applicable' into this field.

Who are you?
Please select...

Location
Please select...

Please select your type of enquiry
☒ I want you to answer a question
☐ I want an unpublished document (maximum 2 documents per request)
☐ I want help identifying which unpublished document I need

For more information on these enquiry types and how we handle them, see:
• [The European Medicines Agency code of good administrative behaviour](#)
• [Access to documents](#)
• [Guide on access to unpublished documents](#)

What is the subject of your enquiry?
For example "Question on", "Request for"

Your question(s)
Please type your clear question or request here.

Please type your clear question or request here. Where possible please provide a link, a product name, a reference number or the name of the document or topic you are interested in. Please do not include any personal data, such as your name or contact details in this field.

Your email address
Enter your email address
We will only use your email address to contact you about your query.

Please retype your email address
Confirm your email address

☐ I have read and agree with the data protection terms [Data protection and privacy](#)

Enter your name

Enter "Not applicable"

Choose "Patient " or " Consumer"

Enter your country

Click "unpublished document"

Enter "Comirnaty/Spikevax"

Copy & paste text on next page

Enter your email address

Confirm your email address

Agree and SUBMIT

3. Copy & paste **this text** into the online form:

I hereby formally request the immediate and unredacted disclosure of the Common Technical Document Modules for Comirnaty and Spikevax, along with substantial additional data regarding the Critical Quality Attributes (CQAs). All documents must be provided in their most current and officially active version at the time of release. Priority in disclosure should follow this ranking: 1.) qPCR Assay for residual DNA measurement, or any other methods applied to quantify residual DNA for Comirnaty as outlined in Procedure EMEA/H/C/005735/II/0202, 29 February 2024, including full data from the 236-batch analysis to validate the analysis submitted to EMA and Spikevax. 2.) CTD Module 2 and 3, particularly regarding CQA (specifications, acceptance criteria, control procedures and analytical results regarding RNA integrity, dsRNA content, residual DNA levels, RNA sequence identity, RNA concentration, bioburden, pH balance, 5' -CAP structure, and Poly(A) tail composition) for Comirnaty and Spikevax. With regard to Comirnaty Modules 3.2.S.2 (Manufacture) and 3.2.S.3 (Characterisation), please be aware of the re-release under ASK-257127. 3.) CTD Modules 4 and 5 for Comirnaty and Spikevax. This request is warranted by an overriding public interest, supported by publicly available evidence suggesting potential risks to human health. Numerous organizations across Europe are actively participating in this urgent appeal and will further substantiate the available evidence of potential harm, reinforcing the need for full disclosure of these critical safety data. Moreover, the undersigned would like to assert the prevailing public interest with regard to the pending case T-623/22, concerning Comirnaty's Specific Obligation Number 1 and CTD Module 3.2.S.3, is currently before the European Court for the unlawful withholding of safety relevant CQA data by EMA and BioNTech under the pretext of Confidential Commercial Information (CCI). As these data are integral to regulatory safety assessments, they do not qualify for CCI protections and must be disclosed under the overriding public interest principle established in EU jurisprudence.

4. You will receive an email confirmation from EMA with an individual ASK-Number in the subject line. Check you spam folder if you don't receive a response from EMA.
5. **IMPORTANT:** Please forward this email to askEMA@NORTHgroup.info
6. That's it – you are part of an historic mass action demanding transparency from the regulator of medical products in the EU.
7. Please share this info but only via email, Telegram, WhatsApp, or Signal – NOT via other social media channels to minimize the risk of EMA closing the web portal.

Thanks for joining the EMA Transparency Initiative!

We will be in touch via email when we receive a reply from EMA and by taking part you consent to allow us to contact you via email about this initiative. If you no longer wish to be contacted by NORTH Group please email notify us at askEMA@NORTHgroup.info.